A-Series

A-Series

Type	Clone production series
Creator	Richard Rambam
Genetic source	Alexandru Ionuț
Manufacturer	Snubable Enterprise
First produced	1999
Discontinued	1 May 2025
Main location	Căciulați, Romania
Era	Vriend Era

A-Series was the main human clone production series created by Richard Rambam at Snubable Enterprise. It used cultured cells derived from Alexandru Ionuț to reconstruct synthetic embryos. The resulting AR lineage developed through an accelerated artificial-gestation process at the main Snubable complex in Căciulați, Romania. Later A-Series production was affected by developmental desynchronization and a progressive microvascular disease known as A-Series ischemic degeneration syndrome.

The series supplied most of the clones used inside Snubable facilities. It also produced units for transport work or armed assignments. Production ended after Rambam was captured and executed on 1 May 2025. The remaining organization surrendered five days later.

History

Rambam and Peter Pecker successfully cloned a stray dog in 1998. Jibbut Snagov began financing their work in February 1999, after which Rambam used biological material taken from Alexandru Ionuț for the first human cloning attempt. The result was unstable, but continued experiments developed into the A-Series. Rambam and Pecker founded Snubable Enterprise on 14 September 1999.

Snubable secured its main Căciulați property on 18 August 2007. The first underground production block was completed on 11 February 2008, and the deep-level maturation wing entered service on 29 September. Internal records stated that earlier facilities and transitional sites had produced about 8,000 to 10,000 clones by the end of that year. The Maturation Synchrony Index entered the production system with the new wing.

A western annex opened on 16 April 2011. It housed equipment used to prepare MAS-GE 1999 and introduced routine whole-transcriptome monitoring for ischemic stress. Cooperation with the Tanoa Einsatzgruppen from 2015 later gave Snubable access to additional equipment and chemicals, but it did not create either monitoring system.

Biological basis

Routine A-Series production did not use donor egg cells. Cultured Alexandru-derived cells were reprogrammed into a totipotent-like state and then assembled into a synthetic embryo. The reset retained Alexandru's genome while changing the regulatory state that limited mature cells to a particular tissue. Descendants of the reprogrammed population produced the developing body and its temporary supporting tissue.

Rambam introduced the accelerated developmental program before embryo assembly. Rapid mitosis expanded cell numbers, but viable development also required each lineage to begin the correct gene-expression program at the correct time. Unequal maturation between tissues could allow the body to keep growing while an organ or part of the skeleton remained behind. Severe desynchronization produced deformity or structural weakness.

Artificial gestation

Early development used placenta-like tissue derived from the reprogrammed source population. The incubator changed to direct vascular support only after the clone's circulation showed sufficient blood flow and cardiac performance. Tissue oxygenation provided a further readiness measure. The transition therefore depended on physiology rather than a fixed incubation day.

The lungs remained fluid-filled during incubation while the vascular interface oxygenated the blood. Removal from the chamber triggered lung-fluid absorption and the first breaths. Pulmonary circulation and lymphatic drainage cleared the remaining fluid. Under mature factory conditions, the complete process reached physical maturity in about 14 days at approximately 37 °C.

Controlled neural stimulation standardized nervous-system development before later conditioning. It did not install learned memories. After the pulmonary transition, staff evaluated each clone's structural condition and cognitive performance before assignment.

Developmental monitoring

The Maturation Synchrony Index measured whether monitored tissues remained on the expected developmental schedule. Transcriptomic reference matching estimated the developmental age of each tissue and the speed at which that age changed. For each tissue, the system selected the larger percentage deviation in age or developmental velocity. The clone-level score was 100 minus the largest tissue divergence.

An MSI of 100 represented complete synchrony. A score below 80 meant that at least one tissue differed from its expected age or velocity by more than 20 percent. This produced a provisional defect flag during incubation. It did not determine the final classification, which still depended on post-incubation evaluation. The incubator acquired successive molecular samples and repeatedly updated the score throughout development.

Classification and records

Clones that failed the physical or cognitive evaluation were classified as Jesters and used for hazardous or low-level work inside controlled facilities. Standard clones met the baseline requirements and formed most of the population. Units with greater physical stability and cognitive performance received the Elite classification and could be selected for armed assignments.

Each clone received a serial in the form AR-XXX-LLLLNNNN. AR identified the Alexandru Rambam lineage. XXX recorded the batch, while LLLL identified the genetic or cognitive classification block. NNNN was the individual unit number. Snubable stored the serial with the clone's production information and operational status.

A-Series ischemic degeneration syndrome

Snubable formally recognized A-Series ischemic degeneration syndrome in 2009. Post-mortem examinations connected several patterns of organ failure to the same process of microvascular injury and ischemic tissue destruction. Inflammatory and proteolytic injury then accelerated damage around the ischemic area. Symptoms could begin days or weeks after apparently successful maturation.

Molecular monitoring and diagnosis

Routine whole-transcriptome ischemic-stress monitoring began in 2011. Circulating RNA from repeated small blood samples supplied a body-wide screening signal. Each transcript was compared with healthy A-Series reference tissue through a gene-wise standardized score. The model combined those results into a raw weighted value called I.

A value of 3.5 or higher produced a warning that required 30 minutes of sustained elevation for confirmation. A value of 7.0 or higher produced a critical alert after 10 minutes. An abnormal circulating-RNA result triggered targeted microscopic sampling of the affected tissue, but molecular stress alone did not establish degeneration.

Formal diagnosis also required evidence of active tissue destruction. Snubable used a combined fragmentomic profile of circulating cell-free DNA. The test compared tissue-specific DNA burden and fragmentation behavior with the clone's late-maturation baseline. It also checked the healthy A-Series population reference. Most assigned clones did not continue receiving this surveillance because Snubable preferred replacement production to long-term care.

Cerebral involvement

Cerebral disease progressed toward liquefactive necrosis. Advanced cases usually developed generalized tonic-clonic seizures that became longer and closer together until continuous convulsive status epilepticus began. Death followed when injury reached areas needed for consciousness or spontaneous breathing. Cardiovascular regulation could also fail.

In rare terminal cases, necrosis weakened the anterior skull base and adjacent tissue. A rupture into a paranasal sinus allowed liquefied intracranial material to reach the upper airway. This drainage was a final manifestation of extensive disease rather than its usual cause of death.

Pulmonary involvement

Pulmonary cases commonly began with increasing cough and shortness of breath. Septic thrombophlebitis near degenerating tissue released infected material into the circulation. Repeated septic embolization then produced multiple lung abscesses. An abscess that opened into a major bronchus could release a large volume of purulent material into the airway. Non-cardiogenic pulmonary edema sometimes added thinner fluid during terminal sepsis.

The respiratory illness could continue for days before blood pressure fell rapidly. Most terminal pulmonary cases ended in systemic circulatory collapse rather than isolated respiratory failure.

Abdominal involvement

The abdominal form centered on pancreatic necrosis. A fistula usually opened into the duodenum. Forceful vomiting could then drive duodenal contents back through the pylorus, carrying inflammatory fluid or necrotic pancreatic material into the stomach.

Persistent vomiting was usually the first visible sign and became bilious before obvious necrotic material appeared. Abnormal pancreatic enzymes raised suspicion when a clone was examined. Contrast-enhanced CT confirmed pancreatic necrosis and could indicate later fistulization. Repeated vomiting caused progressive fluid and electrolyte loss, which led to terminal metabolic collapse.

Later lineage decline

Snubable maintained cryopreserved master stocks and derived working cultures from them. Individual working cultures could be discarded after excessive passage or failed checks. Long-term instability arose because successful adapted sublines were periodically promoted into replacement master banks.

Repeated expansion allowed genomic and epigenetic drift to accumulate. Extreme culture conditions also favored cells that proliferated well during rapid production. Some retained fast growth but became less reliable during differentiation or vascular development. Late-production master stock therefore remained descended from Alexandru without being biologically equivalent to the early lineage.

B-Series stabilization project

Rambam began the B-Series stabilization project in 2023 from archived low-passage A-Series master stock. Fresh Alexandru-derived material could act as a genetic reference, but it was not the project's main starting culture. Earlier endothelial commitment allowed more primitive vessels to form before the fastest organ growth. A perfusion-sensitive safeguard could slow local tissue development when blood supply fell behind.

The project produced a small number of physically mature prototypes. Their organs were better vascularized than those of unstable late A-Series clones, but some capillaries remained too permeable or mechanically weak. The resulting defects included edema and occasional microhemorrhage. Rambam did not approve industrial production before Snubable collapsed.

Later work coordinated pericyte recruitment with formation of the vascular basement membrane. Cellular signalling remained responsible for the main maturation process. The experimental incubator provided closed-loop support only when molecular evidence and functional measurements agreed that a vascular territory was falling behind.

The controller mapped temporary zones around the arterial branches supplying the affected tissue. Doppler ultrasound measured vessel position and blood-flow behavior. Photoacoustic imaging added hemoglobin distribution and tissue oxygenation. Regional correction combined maturation support with small flow changes, avoiding pressure that could damage immature capillaries.

Support was tapered after molecular development and vascular function returned to the expected ranges. The territory then had to remain stable for 30 minutes. Any renewed abnormality reset the timer and restored regional correction. Exact instrument resolution and intervention limits remained unresolved when the project ended.

Operational use and collapse

A-Series clones worked throughout restricted Snubable sites. Snubable Shrankenhaus used them in its plants and loading areas, with about 1,000 assigned to the department at its early-2020s peak. Other units supported transport or guarded perimeters. Elite clones were also deployed as armed security forces.

The loss of Tanoa support on 30 November 2024 weakened Snubable while the Fish Collective attacked its infrastructure. Rambam and Pecker were captured and executed on 1 May 2025. Gustav Shrankenhaus continued the final holdout beneath the Căciulați factory until the remaining organization surrendered on 6 May. A-Series production ended with the dissolution of Snubable Enterprise.

Known clones

Main article: List of clones manufactured by Snubable Enterprise

Known A-Series clones included Snobbina Rambam and Peabard Rambam. Snobbina was assigned to Petru Rambam. Peabard was manufactured in 2014 and became the final surviving clone before his execution on 8 June 2026.

See also

• Richard Rambam
• Alexandru Ionuț
• Snubable Enterprise
• MAS-GE 1999